MCP-1 demonstrated modest diagnostic accuracy for the detection of significant and advanced fibrosis among NASH patients (AUROC of 0.520 and 0.510, respectively) [20]. This evidence concerns the gene CCL2 and metabolic dysfunction-associated steatohepatitis.